Ben Amor Yanis, Nemser Bennett, Singh Angad, Sankin Alyssa, Schluger Neil
Earth Institute, Columbia University, New York, New York 10025, USA.
Emerg Infect Dis. 2008 Sep;14(9):1345-52. doi: 10.3201/eid1409.061524.
Multidrug-resistant tuberculosis (MDR TB) in Africa may be more prevalent than previously appreciated. Factors leading to development of drug resistance need to be understood to develop appropriate control strategies for national programs. We gathered estimates of MDR TB rates for 39 of 46 countries in Africa. The relationship between MDR TB rates and independent factors was analyzed by using correlation and linear regression models. Our findings indicate that drug resistance surveys in Africa are critically needed. MDR TB rates must be assessed in countries without these surveys. In countries that have conducted a drug resistance survey, a new survey will determine evolution of drug resistance rates. We found no correlation between high MDR rates and TB incidence, HIV/TB co-infection rates, or year of introduction of rifampin. Results show that the retreatment failure rate was the most predictive indicator for MDR TB. Current category II drug regimens may increase MDR TB.
非洲的耐多药结核病(MDR TB)可能比之前认为的更为普遍。为国家项目制定适当的控制策略,需要了解导致耐药性产生的因素。我们收集了非洲46个国家中39个国家的耐多药结核病发病率估计值。使用相关性和线性回归模型分析了耐多药结核病发病率与独立因素之间的关系。我们的研究结果表明,非洲迫切需要进行耐药性调查。在尚未开展此类调查的国家必须评估耐多药结核病发病率。在已经进行过耐药性调查的国家,新一轮调查将确定耐药率的变化情况。我们发现高耐多药率与结核病发病率、艾滋病毒/结核病合并感染率或利福平引入年份之间不存在相关性。结果显示,复治失败率是耐多药结核病最具预测性的指标。当前的二类药物治疗方案可能会增加耐多药结核病的发生。